J
James D. Marks
Researcher at University of California, San Francisco
Publications - 338
Citations - 33128
James D. Marks is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Antibody & Monoclonal antibody. The author has an hindex of 82, co-authored 314 publications receiving 32245 citations. Previous affiliations of James D. Marks include University of California & Medical Research Council.
Papers
More filters
Patent
Methods for producing members of specific binding pairs
John Mccafferty,Anthony Richard Pope,Kevin Stuart Johnson,Hoogenboom Hendricus R J M,Andrew D. Griffiths,Ronald Henry Jackson,Kaspar Philipp Holliger,James D. Marks,Timothy Piers Clackson,David John Chiswell,Gregory Paul Winter,Timothy Peter Seattle Bonnert +11 more
TL;DR: In this paper, a member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbps members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof.
Journal ArticleDOI
By-passing immunization: Human antibodies from V-gene libraries displayed on phage
James D. Marks,Hennie R. Hoogenboom,Timothy Peter Bonnert,John McCafferty,Andrew D. Griffiths,Greg Winter +5 more
TL;DR: The results suggest that a single large phage display library can be used to isolate human antibodies against any antigen, by-passing both hybridoma technology and immunization.
Patent
Production of anti-self antibodies from antibody segment repertoires and displayed on phage
Andrew David Griffiths,Hoogenboom Hendricus R J M,James D. Marks,John Mccafferty,Gregory Paul Winter,Geoffrey Walter Grigg +5 more
TL;DR: In this paper, the authors described methods for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self-antigens of that species.
Journal ArticleDOI
By-passing immunization: building high affinity human antibodies by chain shuffling.
James D. Marks,Andrew D. Griffiths,Magnus Malmqvist,Tim Clackson,Jacqueline M. Bye,Greg Winter +5 more
TL;DR: Improved the affinity of one such “primary” antibody is improved by sequentially replacing the heavy and light chain variable (V) region genes with repertoires of V–genes (chain shuffling) obtained from unimmunized donors.
Journal ArticleDOI
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
Dmitri B. Kirpotin,Daryl C. Drummond,Yi Shao,M. Refaat Shalaby,Keelung Hong,Ulrik B. Nielsen,James D. Marks,Christopher C. Benz,John W. Park +8 more
TL;DR: In contrast to nontargeted liposomes, anti-HER2 immunoliposomes achieved intracellular drug delivery via MAb-mediated endocytosis, and this, rather than increased uptake in tumor tissue, was correlated with superior antitumor activity.